Flumazenil: A Complete Overview
Flumazenil is a competitive benzodiazepine receptor antagonist given intravenously, with onset in 1 to 2 minutes and a terminal half-life of roughly 40 to 80 minutes. It is well established for reversing procedural sedation and anesthetic benzodiazepine effect, and far more contentious in overdose, where seizure risk in dependent patients and mixed ingestions, plus re-sedation from its short duration, drive most guideline caution.